Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.
ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.
Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.
The findings suggest that women who experience early menopause (age <40 vs >50 years) may constitute a sex-specific high-risk group for cognitive decline.